News
A once-monthly jab cuts body weight by 16% in groundbreaking obesity trial
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful treatment for obesity. With just a once-monthly shot of 'MariTide,' participants in the study lost as much as 16% of their body weight over the course of a year.
MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...
The once-monthly drug is still under study but could provide added convenience and another option for patients.
Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback